Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Long-Term Deferred Tax (2020 - 2025)

Historic Long-Term Deferred Tax for Cytek Biosciences (CTKB) over the last 6 years, with Q3 2025 value amounting to $38.4 million.

  • Cytek Biosciences' Long-Term Deferred Tax rose 2474.17% to $38.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $38.4 million, marking a year-over-year increase of 2474.17%. This contributed to the annual value of $33.4 million for FY2024, which is 946.96% up from last year.
  • Latest data reveals that Cytek Biosciences reported Long-Term Deferred Tax of $38.4 million as of Q3 2025, which was up 2474.17% from $35.8 million recorded in Q2 2025.
  • Cytek Biosciences' Long-Term Deferred Tax's 5-year high stood at $38.4 million during Q3 2025, with a 5-year trough of $7.4 million in Q2 2021.
  • Moreover, its 5-year median value for Long-Term Deferred Tax was $25.2 million (2023), whereas its average is $23.3 million.
  • Its Long-Term Deferred Tax has fluctuated over the past 5 years, first skyrocketed by 12574.22% in 2023, then skyrocketed by 306.04% in 2025.
  • Over the past 5 years, Cytek Biosciences' Long-Term Deferred Tax (Quarter) stood at $9.2 million in 2021, then surged by 123.03% to $20.5 million in 2022, then surged by 49.02% to $30.5 million in 2023, then increased by 9.47% to $33.4 million in 2024, then grew by 15.04% to $38.4 million in 2025.
  • Its last three reported values are $38.4 million in Q3 2025, $35.8 million for Q2 2025, and $33.7 million during Q1 2025.